chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Heart attack NSTEMI - hospitalized for 2 days at hospital, started new medications, no further incidents
death N17.9 - Acute kidney failure, unspecified E87.1 - Hypo-osmolality and hyponatremia
On January 16, 2008, Pt was given DTaP instead of Td.  Error was discovered 07/17/2008.
Numbness in tongue, right sided facial droop, difficulty closing right eye, headache, jaw pain.  dx with Bell's Palsy
Vaccine recipient verbalize itching and swelling to the throat.  She was noted to be flushed and complained of shortness of breath.  The vaccine recipient received IM epinephrine 0.3mg (0.3ml 1:1000 solution)
I am not sure if there is a connection, but I received a polio booster shot on Jan. 19, pre-overseas travel. After my return, about 7 weeks later overt symptoms began.  I was diagnosed with ideopathic bilateral paralyzed diaphragm. I wonder if there is a 1/1 million chance of a connection.
Covid19 breakthrough. 1st vaccine received on 02/25/2021.   82 y/o  with PMHx AFIB, BPH, CAD with 8 stents, HLD, HTN, CKD stage3, Non-Hodgkins lymphoma, DVT/IVC filter, Pacemaker presents to ED from Rehab with severe SOB and low blood sugar.  Pt was at Rehab after being discharged from hospital with Covid PNA 1/17/2022.  Pt placed on O2 on 2L NC.  CXR-multifocal PNA vs Pulm edema.  On IV ABX and steroids.
swollen lips; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of LIP SWELLING (swollen lips) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LIP SWELLING (swollen lips). At the time of the report, LIP SWELLING (swollen lips) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment details were reported.
This spontaneous report as received from a pharmacist via company representative refers to a patient of unknown age and gender. On 29-NOV-2013, the patient was vaccinated with a 0.65 ml dose of ZOSTAVAX, subcutaneous (lot # and expiration date were not provided). In approximately November 2013, the patient went back to pharmacy to visit the healthcare professional and showed him the hives-like rash at the injection site. Hydrocortisone was given as treatment for the adverse event. The outcome of hives-like rash at the injection site was unknown. Additional information has been requested.
20 eryth/vesicular lesions over torso, few on extremities. Pruritic, sl. tender. After exposure to mom with shingles.
Patient inadvertently given 2nd Moderna dose 8 days early. No harm to patient was reported.
Patient reported of itching 10 minutes after receiving influenza and pneumonia vaccine around 2 PM EST and at 3:30 PM reported of itching all over body. Nurse called emergency line and at that time patient began to have SOB and chest pain.  Nurse was advised to call 911. Nurse called 911 and administered epinephrine.  EMT arrived and took her to hospital.
Post first vax pt had no untoward effects. Post second vax he experienced a fever, chills, and joint aches. By 04/14/00 the aches and fever had improved, on 04/15/00, he experienced a rash allover his body that was described as raised.  The pt was treated with ibuprofen, and Lymerix was discontinued.
pt recvd vax 16SEP95 & 25SEP95 T104 APAP given w/relief, irritable, appetite dec; 27SEP95 T101
Arm pain onset 24 hours after injection continuing through day 6.  Still unresolved.
There was no seriousness criteria reported. Based upon appropriate medical judgement the reported event was considered serious. From initial information received on 4/21/04 from a physician, regarding an adverse event occurring in the USA, it was reported that a 51 year old female patient received a dose of YF VAX, lot number UB363AA, administered SC in the right arm, a dose of TET TOX ADS USP, lot number U1044AA, administered IM in the left arm, a dose of TYPHIM Vi, lot number U1511-2, administered administered IM in the left arm and a dose of HEPATITIS A VACCINE, lot number VHA750AH, administered IM in the right arm on 1/12/04. Three days later, on 1/15/04, the patient experienced irretrievable pain in the right deltoid. The patient was seen by a neurologist and diagnosed with acute brachial neuritis (Parsonage-Turner Syndrome). Treatment included Vioxx and Neurontin once daily. It is unknown whether the patient recovered from these events.    Follow up on 07/16/04 states: "From additional information received on 07/12/04 from the initial reporter, it was reported that the pt was vaccinated at a private doctor's office/hospital in the county and purchased the vaccines with private funds. It was also reported that an EMG completed on 04/16/04 revealed acute brachial neuritis." From additional information received from another manufacturer on 7SEP2004, it was reported that the Hepatitis A vaccine administered to the patient was Havrix, manfaturer GSK. It was also reported that the immunization series with Havrix was discontinued. The event was ongoing as of 6JUL2004. The physician considered the events to be non-serious and to possibly be related to vaccination with Havrix. Reportedly the patient has not recovered from the events.
Information has been received from a physician concerning a 16 year old female patient who on unspecified dates was vaccinated with the first dose and the second dose of GARDASIL vaccine. Concomitant therapy included hepatitis A Vaccine (inactive) (manufacturer unknown) when the patient received the first dose of GARDASIL vaccine. Subsequently, the patient developed 2 nodes on her neck and her "glands" were swollen within 24 hours after receiving the first dose of GARDASIL vaccine. Subsequently, the patient recovered. The physician also noted that the patient experienced the same symptoms after receiving the second dose of GARDASIL vaccine. The patient was seen by the physician. Subsequently, the patient recovered. Additional information has been requested.
Polyarthritis and  livedo reticularis rash within one month after his booster vaccination
Patient has dark and rough and peeling skin around injection site. Some redness extending up to 6 inches from injection site. Patient has been taking prednisone for 3 days to reduce symptoms. Appears to be resolving. Advised patient to get rechecked if no improvement or worsening of area occurs.
Sharp pain in right thigh; Pain in left side of the chest; Sharp pain in right ankle; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sharp pain in right thigh), CHEST PAIN (Pain in left side of the chest) and ARTHRALGIA (Sharp pain in right ankle) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sharp pain in right thigh), CHEST PAIN (Pain in left side of the chest) and ARTHRALGIA (Sharp pain in right ankle). At the time of the report, PAIN IN EXTREMITY (Sharp pain in right thigh), CHEST PAIN (Pain in left side of the chest) and ARTHRALGIA (Sharp pain in right ankle) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
intense diarrhea every 15-30 minutes x 3 days; moderate abdominal, pelvic and rectal pain x 3 days (gradually decreasing on 3rd day); Moderate pain in joints of hips and knees x 1.5 days.; moderate abdominal, pelvic and rectal pain x 3 days (gradually decreasing on 3rd day); moderate abdominal, pelvic and rectal pain x 3 days (gradually decreasing on 3rd day); fever and chills overnight x 1 day; severe pain at injection site x 24 hrs; fever and chills overnight x 1 day; This is a spontaneous report from a contactable consumer or other non-health care professional. A 70-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EN6206), via an unspecified route of administration, administered in Arm Right on 04Mar2021 11:00 as 1st dose, single dose for COVID-19 immunization. Medical history included hypertension, depression, MGUS, prediabetes, neuropathy, anxiety/panic disorder, hypothyroidism from an unknown date and unknown if ongoing. Concomitant medications included cozaar, lipitor, buspar, gabapentin, trazadone, sy taken for an unspecified indication, start and stop date were not reported.  The patient did not receive any other vaccine in four weeks. The patient was not had Covid prior vaccination, and the test was not performed post vaccination. The patient experienced severe pain at injection site x 24 hrs , fever and chills overnight x 1 day, intense diarrhea every 15-30 minutes x 3 days , moderate abdominal, pelvic and rectal pain x 3 days, moderate pain in joints of hips and knees x 1.5 days on 04Mar2021 21:00. The events were assessed as non-serious. The treatment was received for all the events with pepto bismol self-administered. The outcome of the events was reported as recovered on an unspecified date in 2021.  No follow-up attempts are possible. No further information is expected.
Patient reported red spot like rash about 6 inches in length and 1 inch wide from administration site as well as pain at the injection site of moderate level. Patient denied that the rash was raised, itchy or caused any discomfort.
Narrative:  78yo male patient died on 11/25/2021. No information in pt's chart about pt's death or issues leading up to his death. Last chart note dated 10/20/21. Active Problems: Edema (SCT 267038008) Osteopenia (SCT 312894000) History of major orthopedic surgery (SCTHistory of nephrolithiasis (SCT 429025008) History of tonsillectomy (SCT 438759003)History of repair of retinal detachment (SCT 65381000119107) OA - Osteoarthritis (SCT 396275006) Hypothyroidism (SCT 40930008) Pancytopenia (SCT 127034005) Hepatitis C (SCT 50711007) Advanced cirrhosis (SCT 123717006) Hepatic encephalopathy (SCT 13920009) Varices (SCT 128060009) Hypertension, Portal (ICD-9-CM 572.3) Allergies (ICD-9-CM 995.3) Diabetes mellitus type 2 (SCT 44054006) Calcaneal spur (ICD-9-CM 726.73) Pt had received covid vaccines on 1/28/21 & 2/25/21. This death is likely not related to the vaccinations due to patient's comorbidities, advanced age, and length of time from vaccine administration.
Chills, fever of 103F, swelling and redness at the injection site (ca. 2 inch diameter), headaches, light-headedness, dizziness, tendency to vomit.
Not sleepy but tired and fatigued; Not sleepy but tired and fatigued; Slow breathing, but pulse rate was normal; increase palpitation; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A 50 year-old female patient received bnt162b2 (BNT162B2), administration date 26Apr2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Anxiety" (unspecified if ongoing), notes: She explained she also has anxiety and is pre-diabetic; "Pre-diabetic" (unspecified if ongoing), notes: She explained she also has anxiety and is pre-diabetic; "Chondritis" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose number: 1), for Covid-19 immunization. The following information was reported: INSOMNIA (non-serious), FATIGUE (non-serious), outcome "unknown" and all described as "Not sleepy but tired and fatigued"; RESPIRATORY RATE DECREASED (non-serious), outcome "unknown", described as "Slow breathing, but pulse rate was normal"; PALPITATIONS (non-serious), outcome "unknown", described as "increase palpitation".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Mild, overall, but definitely result of the vaccination. Just providing as an FYI. Soreness at the site of injection on my left arm starting several hours after and lasting through the next day.  Took a Tylenol. Extreme lethargy/tiredness about five hours after the injection. Had to take a nap that afternoon and went to bed early.  Felt normal the next day after a night's sleep.
pt recv vax 16OCT97 & approx 24hr p/vax pt exp a rash that resembled mosquito bites on elbows;subsequently this rash turned into hives;pt was seen in ER & treated w/atarax & steroids;
Patient became pale and unresponsive shortly after vaccination. Her breathing was shortened and she appeared to be having a difficult time swallowing saliva so epinephrine was given. EMS was alerted. Patient became responsive shortly after being moved to the floor. At this time she had explained she has passed out twice previously to blood draws. Patient was evaluated by EMS and left the location on her own accord.
SKIN DISCOLORATIONS ON RIGHT SIDE GLUTEUS; DIZZINESS; VERY TIRED; WELT UNDER RIGHT BREAST AND ON STOMACH AREA; VERY NAUSEOUS; This spontaneous report received from a patient concerned a 49 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: asthma, non-smoker, and non-alcoholic user, and other pre-existing medical conditions included: the patient had No known drug allergies. The patient was not pregnant at the time of reporting. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 213021A, expiry: UNKNOWN) dose was not reported, administered on 03-DEC-2021 for prophylactic vaccination. No concomitant medications were reported. On 03-DEC-2021, the patient experienced very nauseous. On 03-DEC-2021, the patient experienced welt under right breast and on stomach area. On 04-DEC-2021, the patient experienced skin discolorations on right side gluteus. On 04-DEC-2021, the patient experienced dizziness. On 04-DEC-2021, the patient experienced very tired. Treatment medications (dates unspecified) included: methylprednisolone, and cetirizine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from dizziness, very nauseous, and very tired on 06-DEC-2021, and had not recovered from skin discolorations on right side gluteus, and welt under right breast and on stomach area. This report was non-serious. This case, from the same reporter is linked to 20211217775.
The HEP A vaccine was administered first then BEXSERO was the second vaccine administered. Within 10 minutes child developed seizure activity and anaphylaxis.
Feb.4th  'shot area' inflamed and itchy.  Redness about half around arm and 6 inches vertical. Feb. 9th(2 wk after) redness has faded.  Red pimply itch spots appear.
pt recvd vax & turned blue, limp & was not responsive this happened 10PM called 911; 4 days later same thing happened;
Sinus symptoms, pressure in the nose, inner earache in both ears, feeling tired. Monday, 06/20/2022 I took a COVID test at a pharmacy, and it was positive. I also went to a walk-in clinic because I wasn?t feeling well, and they retested me there and it was negative. That was within an hour to an hour and a half. Their diagnosis was a sinus infection and right ear infection.
Got the vaccine, got home, and noticed itching in the area of the vaccine, on her hands and her both arms.  She has severe itching, has been rubbing lotion on it.
1. Night of the vaccine, 11/12/19, chills, extreme shivers, slight fever of one degree, malaise, inability to sleep, muscle soreness all over body. 2. Next day 11/13/19, shivers and fever subsided, continued malaise and muscle soreness. Appearance of very dark bruise at injection site. 3. Next day, 11/14/19, felt better in terms of malaise but  a  raised, pink, hot rash appeared 2 inches BELOW the injection site. The rash was approx 4 inches horizontally across upper outer left arm and approx 3 inched lengthwise. So a rectangle of 4"x3," appearing as if someone had slapped me hard laterally across the arm. It felt warm to the touch. It did NOT itch. It was very marked and surprising to anyone who saw it. I called the pharmacist who said that as long as it faded and I felt ok that it was possibly a reaction from the vaccination but that would go away on its own. Since I did FEEL better and was not in pain, I decided to wait and see rather than go to my doctor.  Over the next several days, it gradually faded away without issue. Today 11/20/19 it is only barely visible as a slight pink blush. The blue bruise is fading but is still quite visible at the injection site.
Induration surrounding injection site. 16 X 18cm area of edema surrounding site. Information from Follow-up report states I have received follow-up information on the VAERS report #241798. I spoke with the MD on this patient. She indicated the reaction to the Menactra vaccination. The patient tool Tylenol for 2 days, the swelling on the arm lasted for 5 days, and that the subject had guarded use of that arm. She state that he really didn't even want to lift it, but would if he had to. No other symptoms were reported.
Morning following  the day of injection  very achy all over, extremely tired, coughing,  later that afternoon 2 degree fever as well as the  evening.  Chills.  Felt some better the next day, not as good that evening.   Today is 3 days after injection  still tired  and  quite a bit of coughing.
Patient stated she was not feeling well after her first dose of pfizer covid vaccine.  Patient had seizure like activity and was unconscious for a about 15-30 seconds.  an ambulance was called vitals were taken.  patient and patent family declined transport to medical facility.
Face numbness; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318), via an unspecified route of administration in the arm left on 01Apr2021 at 11:00 (at the age of 38-year-old), as a single dose for COVID-19 immunisation. Medical history included factor V deficiency (Factor 5 as reported). Concomitant medications included fluticasone propionate (FLONAZE) from an unknown date for an unknown indication.  The patient had no known allergies (not that I know of, as reported). The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 11:15, the patient experienced face numbness from the cheeks down. The patient did not receive any treatment for the event. The clinical outcome of the event face numbness was not resolved.  No follow-up attempts are needed. No further information is expected.
No other AE information given at this time; HCP calling to report patient was given PNEUMOV AX 23 that was recalled; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. Information about patient's pertinent concurrent conditions, medical history, concomitant medications and previous drug reactions or allergies were not provided.  On 09-OCT-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) which was recalled at a dose of 0.5 milliliter as prophylaxis (concentration, number of administered dose, route and anatomical location of administration; lot # S036495, expiration date reported 13-SEP-2021) (recalled product administered). No adverse events were reported. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: S036495; expirationdate: 13-SEP-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
This report describes the occurrence of mercury poisoning in a female child of unspecified age who was vaccinated with hepatitis B vaccine for prophylaxis. This report was received as part of litigation proceedings and has not been verified by a physician or other healthcare professional. The subject's medical history, concurrent conditions, and concurrent medications were not reported. This subject received injections of hepatitis B vaccine on 3/10/94, 5/11/94, and 9/14/94. She also received combination diphtheria and tetanus toxoids and pertussis/Haemophilus influenzae type B conjugate vaccine, oral poliomyelitis virus vaccine, and MMR. She also received a tuberculin skin test. The subject's attorney alleged that, as a result of the vaccines administered, the subject suffers from the effects of mercury poisoning. The mercury poisoning in this report is considered medically serious (OMIC).
Client developed Opsoclonus myoclonus syndrome 3 days after being vaccinated. The 60 day follow up received on 8/29/03 states pt is slowly regaining his abilities. He is not walking alone yet. Receiving IVIG monthly. Getting therapy and has improved. Speech slowly returning and muscles less "jerky" eyes less "dancing." The medical records state trembling. Information received from Discharge Summary states trembling, screaming, agitation, ataxic and sinusitis. msv
No other AE; temperature excursion; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not reported.   On 05-NOV-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # U019905, expiration date 24-JUN-2023, at a dose of 0.5 milliliter for prophylaxis (vaccination scheme frequency, route of administration and anatomical site of vaccination were not reported).   The vaccine was stored in a temperature of 20 degree Fahrenheit for 17 (unspecified time unit). There was no previous temperature excursion reported.
Approximately 1 week after vaccination patient developed swelling and blistering rash overlying left arm.  Subsequently developed significant pain and weakness in his arm, with contractures present.